Surgical Treatment Of Stage IIIB Non-Small Cell Lung Cancer After Induction-Chemoradiotherapy
- Determine the incidence of radically resected disease in patients with stage IIIB
non-small cell lung cancer treated with induction cisplatin, etoposide, and
radiotherapy followed by surgical resection.
- Determine the toxicity (morbidity and mortality) of this regimen in these patients.
- Determine the clinical response rate and pathological response rate in patients treated
with this regimen.
OUTLINE: This is a multicenter study.
Patients receive induction chemotherapy comprising cisplatin IV on day 1 and etoposide IV on
days 1-3. Chemotherapy repeats every 3 weeks for 3 courses. Beginning on day 2 of the second
course of chemotherapy, patients undergo induction radiotherapy once daily 5 days a week for
5-7 weeks. Chemoradiotherapy continues in the absence of disease progression or unacceptable
At 3-6 weeks after completion of the last dose of induction radiotherapy, patients undergo
lobectomy or pneumonectomy.
Patients are followed at 30 days and 4 months, every 6 months for 2 years, and then annually
PROJECTED ACCRUAL: A total of 27-62 patients will be accrued for this study.
Primary Purpose: Treatment
Rob Van Klaveren, MD, PhD
University Medical Center Rotterdam at Erasmus Medical Center
United States: Federal Government